Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2022

22.12.2021 | short review

New targeted therapies in kidney cancer

verfasst von: MD Karl Mayrhofer, MD, MBA Dora Niedersüß-Beke

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

New agents and combinations continue to change the clinical practice of treating patients with renal cell carcinoma. In this review we want to highlight the most recent therapeutic developments and also give an overview of the current standard of care in advanced disease. Studies investigating lenvatinib plus pembrolizumab, belzutifan and cabozantinib are discussed.
Literatur
1.
Zurück zum Zitat Motzer R, Alekseev B, Rha S‑Y, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300. CrossRef Motzer R, Alekseev B, Rha S‑Y, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300. CrossRef
2.
Zurück zum Zitat Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82. CrossRef Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82. CrossRef
3.
Zurück zum Zitat Bauer TM, Choueiri TK, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. The oral HIF‑2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): updated follow-up of a phase I/II study. J Clin Oncol. 2021;39(6_suppl):273. CrossRef Bauer TM, Choueiri TK, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. The oral HIF‑2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): updated follow-up of a phase I/II study. J Clin Oncol. 2021;39(6_suppl):273. CrossRef
4.
Zurück zum Zitat Srinivasan R, Donskov F, Iliopoulos O, Rathmell WK, Narayan V, Maughan BL, et al. Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(15_suppl):4555. CrossRef Srinivasan R, Donskov F, Iliopoulos O, Rathmell WK, Narayan V, Maughan BL, et al. Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(15_suppl):4555. CrossRef
5.
Zurück zum Zitat Choueiri TK, Bauer TM, McDermott DF, Arrowsmith E, Roy A, Perini RF, et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(6_suppl):272. CrossRef Choueiri TK, Bauer TM, McDermott DF, Arrowsmith E, Roy A, Perini RF, et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(6_suppl):272. CrossRef
6.
Zurück zum Zitat Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–88. CrossRef Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–88. CrossRef
7.
Zurück zum Zitat Song SH, Jeong IG, You D, Hong JH, Hong BS, Song C, et al. VEGF/VEGFR2 OR PDGF-β/PDGFR‑β expression in non-metastatic, renal cell carcinoma: a prospective study WiTH 1,091 consecutive cases. Int J Clin Exp Pathol. 2014;7:7681–9. Song SH, Jeong IG, You D, Hong JH, Hong BS, Song C, et al. VEGF/VEGFR2 OR PDGF-β/PDGFR‑β expression in non-metastatic, renal cell carcinoma: a prospective study WiTH 1,091 consecutive cases. Int J Clin Exp Pathol. 2014;7:7681–9.
8.
Zurück zum Zitat The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45. CrossRef The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45. CrossRef
9.
Zurück zum Zitat Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. CrossRef Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. CrossRef
11.
Zurück zum Zitat Lee C‑H, Voss MH, Carlo MI, Chen Y‑B, Reznik E, Knezevic A, et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial. J Clin Oncol. 2021;39(15_suppl):4509. CrossRef Lee C‑H, Voss MH, Carlo MI, Chen Y‑B, Reznik E, Knezevic A, et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial. J Clin Oncol. 2021;39(15_suppl):4509. CrossRef
12.
Zurück zum Zitat Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–41. CrossRef Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–41. CrossRef
13.
Zurück zum Zitat Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. CrossRef Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. CrossRef
14.
Zurück zum Zitat Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. CrossRef Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. CrossRef
Metadaten
Titel
New targeted therapies in kidney cancer
verfasst von
MD Karl Mayrhofer
MD, MBA Dora Niedersüß-Beke
Publikationsdatum
22.12.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00782-6